LipGYNieuwlaatRPistersRLaneDACrijnsHJ.Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263-272.
2.
PistersRLaneDANieuwlaatRde VosCBCrijnsHJLipGY.A novel user-friendly score (HAS-BLED) to assess one year risk of major bleeding in atrial fibrillation patients: the Euro Heart Survey. Chest. 2010;138:1093-1100.
3.
GageBFYanYMilliganPEet al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151:713-719.
4.
Chai-AdisaksophaCCrowtherMIsayamaTLimW.The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood. 2014;124:2450-2458.
5.
ConnollySJEzekowitzMDYusufSet al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
6.
PatelMRMahaffeyKWGargJet al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.
7.
GrangerCBAlexanderJHMcMurrayJJet al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.
8.
GuiglianoRPRuffCTBraunwaldEet al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093-2104.
